Loading...
Market
Attruby sales exceed $500 million in first year by Nov 23, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
BridgeBio Pharma's official financial reports and press releases
Story
FDA Approves BridgeBio's Attruby (Acoramidis), First Near-Complete TTR Stabilizer for ATTR-CM
Nov 23, 2024, 12:14 AM
BridgeBio Pharma (ticker symbol $BBIO) announced that the U.S. Food and Drug Administration (FDA) has approved Attruby™ (acoramidis), an orally administered near-complete transthyretin (TTR) stabilizer for the treatment of adult patients with transthyretin cardiac amyloidosis (ATTR-CM). Attruby, the first and only approved product specifying near-complete stabilization of TTR (≥90%), was designed to mimic a naturally occurring 'rescue mutation' of the TTR gene (T119M), targeting the root cause of ATTR-CM by preventing destabilization of the native TTR tetramer. The drug is approved to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients. The approval sets up competition with Pfizer, which also markets a treatment for ATTR-CM. Attruby will be priced at approximately $245,000 per year.
View original story
Similar markets
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Under $500M • 25%
$500M - $1B • 25%
$1B - $2B • 25%
Over $2B • 25%